Navigation Links
Pharmacopeia to Present at The Roth 20th Annual OC Growth Stock Conference
Date:2/13/2008

PRINCETON, N.J., Feb. 13 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced that Dr. Leslie J. Browne, President and Chief Executive Officer, will deliver a corporate presentation at the Roth 20th Annual OC Growth Stock Conference. The conference will be held February 18-21, 2008, at The Ritz Carlton Laguna Niguel in Dana Point, CA.

Dr. Browne's presentation will take place at 10:30 a.m. local time on Thursday, February 21st. The presentation will include an overview of the company's drug development pipeline, including an update on its internal clinical programs, PS433540 (DARA), which is progressing in Phase 2, and PS178990 (SARM), which is currently in Phase 1. A live webcast and 90-day archive of the presentation can be accessed at http://www.pharmacopeia.com.

ABOUT PHARMACOPEIA

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including seven clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic agreements with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at http://www.pharmacopeia.com.

Contact:

Amy P. Sharpless

Corporate Communications

(609) 452-3643

ir_pr@pcop.com

This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 2 and Phase 1 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS178990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS031291, a product candidate from its chemokine receptor CCR1 program, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540, PS178990 and PS031291, Pharmacopeia's ability to successfully perform under its collaborations with Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Schering-Plough and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. USP publishes Spanish edition of United States Pharmacopeia and National Formulary
2. USP Publishes Spanish Edition of United States Pharmacopeia and National Formulary
3. U.S. Pharmacopeia 8th Annual MEDMARX(R) Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide
4. US Pharmacopeia partners with Quantros to enhance the MEDMARX patient safety reporting program
5. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
6. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
7. Pharmacopeia Announces Senior Additions to Management Team
8. Pet DRx to Present at Roth 20th Annual OC Growth Stock Conference
9. AtriCure to Present at Roth Capital Partners 20th Annual OC Conference
10. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference
11. Inexpensive Online Pain Education Program for Physicians as Effective as Live Presentations by National Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic and medical ... which launched October 17, 2016, features comprehensive information regarding a wide range of ... and patients can discover the latest clinical dermatology treatments for medical skin concerns ...
(Date:12/7/2016)... ... 2016 , ... Texas Premier Locksmith , a leading ... unethical locksmith companies and is urging Search Engines to improve verification methods in ... Locksmith, these fraudulent locksmith services take advantage of consumers locked out of houses, ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX editors to ... Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes 30 flip ... zones. Editors can select from a variety of flip book animations. In Addition, users ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... Infertility and Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin ... has a team of three acupuncturists to help patients realize their family building ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Walking With God: Inspirational Lessons from My ... the reader to be aware of God's direction in their lives. “Walking With God: ... retired teacher and active church leader. , Sanford says, “I enjoy sharing ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... 6, 2016  "Blood Tests replace Surgical Biopsies. ... The Diagnostic, Monitoring and Screening Test opportunities ... is occurring using in vitro blood testing to ... impressive backing, has announced a single blood test ... faster than the market. New technology that definitively ...
(Date:12/6/2016)... 2016 Anaplastic Oligoastrocytoma - Pipeline Review, ... latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic ... overview of the Anaplastic Oligoastrocytoma (Oncology) pipeline landscape. ... forms when two types of cells in the ... number to form a mass. These brain cells ...
(Date:12/6/2016)... 2016 Eurofins Genomics today announced it ... of American Pathologists (CAP) and certification under the ... laboratory in Louisville, KY , ... headquarters. "Our new CLIA-licensed and CAP-accredited ... still considered the ,Gold Standard, method for validation ...
Breaking Medicine Technology: